Pharmaceuticals earnings: latest results compared
The latest quarter from Eli Lilly, Johnson & Johnson, AbbVie, Merck, Pfizer, Amgen, Gilead Sciences and Bristol Myers Squibb, side by side. Revenue is as reported; growth and operating margin are calculated from XBRL filings once the 10-Q or 10-K is in.
| Latest quarter | Revenue | Growth vs year ago | Operating margin | Reported |
|---|---|---|---|---|
 Eli Lilly Q3 2026 | $24.4B | +38.6% | — | 29 Oct 2026 |
 Johnson & Johnson Q3 FY2026 | $25.4B | +5.9% | — | 13 Oct 2026 |
 AbbVie Q3 2026 | $17.4B | +10.3% | 36.0% | 30 Oct 2026 |
 Merck Q3 2026 | $18.1B | +4.7% | — | 29 Oct 2026 |
 Pfizer Q3 2026 | $16.6B | −0.4% | — | 3 Nov 2026 |
 Amgen Q3 2026 | $10.4B | +8.5% | 35.8% | 3 Nov 2026 |
 Gilead Sciences Q3 2026 | $8.3B | +6.8% | 41.7% | 29 Oct 2026 |
 Bristol Myers Squibb Q3 2026 | $13.1B | +6.9% | — | 29 Oct 2026 |
What each company reported
- 3 Nov 2026Pfizer Q3 2026 · Pfizer reported third-quarter 2026 Revenues of $16.6 Billion, Reported Diluted EPS of $0.56 and Adjusted Diluted EPS of $0.87, and raised full-year 2026…Transcript · Slides
- 3 Nov 2026Amgen Q3 2026 · Amgen's third quarter 2026 total revenues increased 8% to $10.4 billion, with GAAP EPS up 19% from $5.93 to $7.08 and non-GAAP EPS up 14% from $5.64 to $6.45.Transcript
- 30 Oct 2026AbbVie Q3 2026 · AbbVie reported third-quarter net revenues of $17.404 billion, an increase of 10.3 percent on a reported basis, with diluted EPS of $2.37 on a GAAP basis and…Transcript
- 29 Oct 2026Eli Lilly Q3 2026 · Revenue in Q3 2026 increased 39% to $24.4 billion driven primarily by Mounjaro and Zepbound, with EPS of $7.22 on a reported basis and $7.48 on a non-GAAP…Transcript
- 29 Oct 2026Merck Q3 2026 · Merck reported third-quarter 2026 Total Worldwide Sales of $18.1 Billion (5% Growth; 4% Growth ex-FX), GAAP EPS of $2.04 and Non-GAAP EPS of $2.49, both…Transcript
- 29 Oct 2026Gilead Sciences Q3 2026 · Gilead's third quarter 2026 product sales excluding Veklury increased 16% year-over-year to $8.2 billion and Biktarvy sales increased 10% to $4.1 billion, with…Transcript · Slides
- 29 Oct 2026Bristol Myers Squibb Q3 2026 · Third quarter revenues increased 7% to $13.1 billion; GAAP EPS was $1.05 and non-GAAP EPS was $1.35, and 2026 revenue guidance was raised to a range of $49.75…Transcript
- 13 Oct 2026Johnson & Johnson Q3 FY2026 · Johnson & Johnson reported Q3 2026 sales growth of 5.9% to $25.4 Billion, with EPS of $0.09 (after a one-time special charge for the proposed talc litigation…Transcript · Slides
Every quarter and KPI history
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Pfizer (PFE)Amgen (AMGN)Gilead Sciences (GILD)Bristol Myers Squibb (BMY)